Current role
Biotechnology · Healthcare
CFO, Chief Accounting Officer
2023-09-01–present
Scott Burrows
Chief Accounting Officer
Spyre Therapeutics, Inc. (SYRE)Equibles does not estimate personal net worth.
Get an email with a short summary when Spyre Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SYRE alertsAbout Scott Burrows
Scott Burrows is recorded as Chief Accounting Officer at Spyre Therapeutics, Inc. (SYRE) since September 1, 2023 and CFO at Spyre Therapeutics, Inc. (SYRE). The newest filing on record that lists Scott Burrows as CFO at Spyre Therapeutics, Inc. (SYRE) is dated April 10, 2026. Spyre Therapeutics, Inc. reported in an 8-K filed September 5, 2023 that Scott Burrows was appointed Chief Financial Officer. Spyre Therapeutics, Inc. reported in an 8-K filed September 5, 2023 that Scott Burrows was appointed principal accounting officer, effective September 1, 2023. Spyre Therapeutics, Inc. reported in an 8-K filed September 5, 2023 that Scott Burrows was appointed Chief Financial Officer, effective September 1, 2023. The proxy statement of Spyre Therapeutics, Inc. reports total compensation of $2,192,045 for Scott Burrows in fiscal 2025, including a base salary of $490,000. Disclosed compensation is on record for 3 fiscal years. Spyre Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Spyre Therapeutics, Inc. includes Cameron Turtle (CEO, COO and Board Member), Cameron Turtle, DPhil (CEO and Board Member), James Kastenmayer (CEO) and 7 others.
“today announced the appointment of Scott Burrows, as Chief Financial Officer and Heidy Abreu King-Jones as Chief Legal Officer and Corporate Secretary.”
“Mr. Burrows will also succeed Mr. Alspaugh as the principal financial officer and principal accounting officer of the Company on the Effective Date.”
Affiliation history
-
Current
2023-09-01–present
-
Current
Start not stated–present
Last confirmed April 10, 2026
Company network
Leadership on record at Spyre Therapeutics, Inc.
- Cameron Turtle CEO, COO, Board Member
- Cameron Turtle, DPhil CEO, Board Member
- James Kastenmayer CEO
- Jeffrey M. Goldberg CEO
- Heidy Abreu King-Jones General Counsel
- Jonathan Alspaugh Chief Accounting Officer
- Steven Weber Chief Accounting Officer
- Jeffrey Albers Board Member
- Laurie Stelzer Board Member
- Mark McKenna Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | $490,000 | $2,192,045 |
| 2024 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | $475,000 | $2,207,366 |
| 2023 | Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | $154,589 | $7,551,539 |